Akero Therapeutics, Inc.

NasdaqGS AKRO

Akero Therapeutics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -83,528.87%

Akero Therapeutics, Inc. Net Income Margin is -83,528.87% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: AKRO

Akero Therapeutics, Inc.

CEO	Dr. Andrew Cheng M.D., Ph.D.
IPO Date	June 20, 2019
Location	United States
Headquarters	601 Gateway Boulevard
Employees	60
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Key trends

Past 5 years